The 2-year invasive disease-free survival rate was 93.9% in the neratinib group and 91.6% in the placebo group (HR 0.67, 95% CI 0.50 – 0.91, p=0.0091).r
Kaplan-Meier curves for invasive disease-free survival (A) and disease-free survival including ductal carcinoma in situ (B) in the intention-to-treat populationr
© Lancet oncol 2016
The 5-year invasive disease-free survival rates were 90.2% in the neratinib group compared with 87.7% in the placebo group (HR 0.73, 95% CI 0.57 – 0.92, p = 0.0083). Secondary endpoints, such as distant disease-free survival and time to distant recurrence were not met. Overall survival data are not yet mature.r
In the updated analysis, for the subgroup of patients with hormone receptor-positive disease, the HR for invasive disease-free survival in the neratinib group compared with the placebo group was 0.60 (95% CI 0.43 – 0.83), whereas for the patients with hormone receptor-negative disease, the HR for invasive disease-free survival was 0.95 (95% CI 0.66 – 1.35).
Kaplan-Meier curves for invasive disease-free survival for A) ITT population, B) patients with hormone receptor-positive breast cancer and C) hormone receptor-negative breast cancerr
© Lancet oncol 2017